0IFK.LSE Editas Medicine, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-82.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0IFK.LSE undervalued?

Graham number

The Graham number of Editas Medicine, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Editas Medicine, Inc. fundamental analysis

No fundamental analysis for Editas Medicine, Inc. yet.

Editas Medicine, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-de…

Full company profile